Skip to main content
Erschienen in: Pediatric Radiology 12/2015

01.11.2015 | Original Article

Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies

verfasst von: Csilla Balassy, Donna Roberts, Stephen F. Miller

Erschienen in: Pediatric Radiology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Gadoteric acid is a paramagnetic gadolinium macrocyclic contrast agent approved for use in MRI of cerebral and spinal lesions and for body imaging.

Objective

To investigate the safety and efficacy of gadoteric acid in children by extensively reviewing clinical and post-marketing observational studies.

Materials and methods

Data were collected from 3,810 children (ages 3 days to 17 years) investigated in seven clinical trials of central nervous system (CNS) imaging (n = 141) and six post-marketing observational studies of CNS, musculoskeletal and whole-body MR imaging (n = 3,669). Of these, 3,569 children were 2–17 years of age and 241 were younger than 2 years. Gadoteric acid was generally administered at a dose of 0.1 mmol/kg. We evaluated image quality, lesion detection and border delineation, and the safety of gadoteric acid. We also reviewed post-marketing pharmacovigilance experience.

Results

Consistent with findings in adults, gadoteric acid was effective in children for improving image quality compared with T1-W unenhanced sequences, providing diagnostic improvement, and often influencing the therapeutic approach, resulting in treatment modifications. In studies assessing neurological tumors, gadoteric acid improved border delineation, internal morphology and contrast enhancement compared to unenhanced MR imaging. Gadoteric acid has a well-established safety profile. Among all studies, a total of 10 children experienced 20 adverse events, 7 of which were thought to be related to gadoteric acid. No serious adverse events were reported in any study. Post-marketing pharmacovigilance experience did not find any specific safety concern.

Conclusion

Gadoteric acid was associated with improved lesion detection and delineation and is an effective and well-tolerated contrast agent for use in children.
Literatur
1.
Zurück zum Zitat MacKenzie JD, Vasanawala SS (2010) State-of-the-art in pediatric body and musculoskeletal magnetic resonance imaging. Semin Ultrasound CT MR 31:86–99CrossRefPubMed MacKenzie JD, Vasanawala SS (2010) State-of-the-art in pediatric body and musculoskeletal magnetic resonance imaging. Semin Ultrasound CT MR 31:86–99CrossRefPubMed
2.
Zurück zum Zitat Hervé-Somma CM, Sebag GH, Prieur AM et al (1992) Juvenile rheumatoid arthritis of the knee: MR evaluation with Gd-DOTA. Radiology 182:93–98CrossRefPubMed Hervé-Somma CM, Sebag GH, Prieur AM et al (1992) Juvenile rheumatoid arthritis of the knee: MR evaluation with Gd-DOTA. Radiology 182:93–98CrossRefPubMed
3.
Zurück zum Zitat Bonnerot V, Sebag G, de Montalembert M et al (1994) Gadolinium-DOTA enhanced MRI of painful osseous crises in children with sickle cell anemia. Pediatr Radiol 24:92–95CrossRefPubMed Bonnerot V, Sebag G, de Montalembert M et al (1994) Gadolinium-DOTA enhanced MRI of painful osseous crises in children with sickle cell anemia. Pediatr Radiol 24:92–95CrossRefPubMed
4.
Zurück zum Zitat Ducou le Pointe H, Haddad S, Silberman B et al (1994) Legg–Perthes–Calve disease: staging by MRI using gadolinium. Pediatr Radiol 24:88–91CrossRefPubMed Ducou le Pointe H, Haddad S, Silberman B et al (1994) Legg–Perthes–Calve disease: staging by MRI using gadolinium. Pediatr Radiol 24:88–91CrossRefPubMed
5.
Zurück zum Zitat Hanquinet S, Christophe C, Greef DD et al (1996) Clinical evaluation of gadodiamide injection in paediatric MR imaging. Pediatr Radiol 26:806–810CrossRefPubMed Hanquinet S, Christophe C, Greef DD et al (1996) Clinical evaluation of gadodiamide injection in paediatric MR imaging. Pediatr Radiol 26:806–810CrossRefPubMed
6.
Zurück zum Zitat Lundby B, Gordon P, Hugo F (1996) MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications. Eur J Radiol 23:190–196CrossRefPubMed Lundby B, Gordon P, Hugo F (1996) MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications. Eur J Radiol 23:190–196CrossRefPubMed
7.
Zurück zum Zitat Lowe LH, Kearns GL, Wible JH Jr (2006) The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Curr Med Res Opin 22:2515–2524CrossRefPubMed Lowe LH, Kearns GL, Wible JH Jr (2006) The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Curr Med Res Opin 22:2515–2524CrossRefPubMed
8.
Zurück zum Zitat Barkovich A, Raybaud C (2011) Pediatric neuroimaging, 5th edn. Lippincott Williams & Wilkins, Philadelphia Barkovich A, Raybaud C (2011) Pediatric neuroimaging, 5th edn. Lippincott Williams & Wilkins, Philadelphia
10.
Zurück zum Zitat Colosimo C, Demaerel P, Tortori-Donati P et al (2005) Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumors in children. Pediatr Radiol 35:501–510CrossRefPubMed Colosimo C, Demaerel P, Tortori-Donati P et al (2005) Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumors in children. Pediatr Radiol 35:501–510CrossRefPubMed
11.
Zurück zum Zitat Balassy C, Hörmann M (2008) Role of MRI in paediatric musculoskeletal conditions. Eur J Radiol 68:245–258CrossRefPubMed Balassy C, Hörmann M (2008) Role of MRI in paediatric musculoskeletal conditions. Eur J Radiol 68:245–258CrossRefPubMed
12.
Zurück zum Zitat Riccabona M (2008) MRI in neonates, infants and children — overuse or still insufficient availability for paediatric needs? Eur J Radiol 68:189–190CrossRef Riccabona M (2008) MRI in neonates, infants and children — overuse or still insufficient availability for paediatric needs? Eur J Radiol 68:189–190CrossRef
13.
Zurück zum Zitat Dagia C, Ditchfield M (2008) 3T MRI in paediatrics: challenges and clinical applications. Eur J Radiol 68:309–319CrossRef Dagia C, Ditchfield M (2008) 3T MRI in paediatrics: challenges and clinical applications. Eur J Radiol 68:309–319CrossRef
14.
Zurück zum Zitat Port M, Idée JM, Medina C et al (2008) Efficiency thermodynamics and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21:469–490CrossRefPubMed Port M, Idée JM, Medina C et al (2008) Efficiency thermodynamics and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21:469–490CrossRefPubMed
15.
Zurück zum Zitat Fretellier N, Idée JM, Bruneval P et al (2012) Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Brit J Pharmacol 165:1151–1162CrossRef Fretellier N, Idée JM, Bruneval P et al (2012) Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Brit J Pharmacol 165:1151–1162CrossRef
16.
Zurück zum Zitat Haylor J, Schroeder J, Wagner B et al (2012) Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. Radiology 263:107–116CrossRefPubMed Haylor J, Schroeder J, Wagner B et al (2012) Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. Radiology 263:107–116CrossRefPubMed
17.
Zurück zum Zitat Grobner T (2006) Gadolinium — a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108CrossRefPubMed Grobner T (2006) Gadolinium — a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108CrossRefPubMed
18.
Zurück zum Zitat Kang JW, Lim TH, Choi CG et al (2010) Evaluation of contrast-enhanced magnetic resonance angiography (MRA) using Gd-DOTA compared with time-of-flight MRA in the diagnosis of clinically significant non-coronary arterial disease. Eur Radiol 20:1934–1944CrossRefPubMed Kang JW, Lim TH, Choi CG et al (2010) Evaluation of contrast-enhanced magnetic resonance angiography (MRA) using Gd-DOTA compared with time-of-flight MRA in the diagnosis of clinically significant non-coronary arterial disease. Eur Radiol 20:1934–1944CrossRefPubMed
19.
Zurück zum Zitat Maurer M, Heine O, Wolf M et al (2012) Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol 81:885–890CrossRefPubMed Maurer M, Heine O, Wolf M et al (2012) Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol 81:885–890CrossRefPubMed
20.
Zurück zum Zitat Ishiguchi T, Takahashi S (2010) Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D 10:133–145PubMedCentralCrossRefPubMed Ishiguchi T, Takahashi S (2010) Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D 10:133–145PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Meng H, Grosse-Wortmann L (2012) Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice. J Cardiovasc Magn Reson 14:56PubMedCentralCrossRefPubMed Meng H, Grosse-Wortmann L (2012) Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice. J Cardiovasc Magn Reson 14:56PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Neiss AC, Le Mignon MM, Vitry A et al (1991) Efficacy and safety of DOTA-Gd from a European multicenter survey. Preliminary results on 4,169 cases. Rev Im Med 3:383–387 Neiss AC, Le Mignon MM, Vitry A et al (1991) Efficacy and safety of DOTA-Gd from a European multicenter survey. Preliminary results on 4,169 cases. Rev Im Med 3:383–387
23.
Zurück zum Zitat Briand Y, Neiss AC, Vitry A et al (1992) Efficacy and safety of the macrocyclic complex Gd-DOTA in children: results of a multi-centre study. Proceedings of the 29th Congress of the European Society of Pediatric Radiology, 128 Briand Y, Neiss AC, Vitry A et al (1992) Efficacy and safety of the macrocyclic complex Gd-DOTA in children: results of a multi-centre study. Proceedings of the 29th Congress of the European Society of Pediatric Radiology, 128
24.
Zurück zum Zitat Pracros JP, de la Garanderie J (2012) The SECURE study: observational post-marketing study on the safety of meglumine gadoterate — interim analysis of 972 children. Pediatr Radiol 42:S511–S512 Pracros JP, de la Garanderie J (2012) The SECURE study: observational post-marketing study on the safety of meglumine gadoterate — interim analysis of 972 children. Pediatr Radiol 42:S511–S512
25.
Zurück zum Zitat Emond S, Brunelle F (2011) Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. Pediatr Radiol 41:1401–1406CrossRefPubMed Emond S, Brunelle F (2011) Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. Pediatr Radiol 41:1401–1406CrossRefPubMed
26.
Zurück zum Zitat Pathkar D (2012) SECURE study (abstract): observational post-marketing study on the safety of meglumine gadoterate (Gd-DOTA) — interim analysis on 21,447 patients. J Med Imaging Radiat Oncol 56:134 Pathkar D (2012) SECURE study (abstract): observational post-marketing study on the safety of meglumine gadoterate (Gd-DOTA) — interim analysis on 21,447 patients. J Med Imaging Radiat Oncol 56:134
27.
Zurück zum Zitat Pearce MS, Salotti JA, Little MP et al (2012) Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 380:499–505PubMedCentralCrossRefPubMed Pearce MS, Salotti JA, Little MP et al (2012) Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 380:499–505PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Ylänen K, Poutanen T, Savikurki-Heikkilä P et al (2013) Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol 61:1539–1547CrossRefPubMed Ylänen K, Poutanen T, Savikurki-Heikkilä P et al (2013) Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol 61:1539–1547CrossRefPubMed
29.
Zurück zum Zitat Martí-Bonmatí L, Vega T, Benito C et al (2000) Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: phase III open multicenter study. Invest Radiol 35:141–147CrossRefPubMed Martí-Bonmatí L, Vega T, Benito C et al (2000) Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: phase III open multicenter study. Invest Radiol 35:141–147CrossRefPubMed
30.
Zurück zum Zitat Sebag G, Ducou Le Pointe H, Klein I et al (1997) Dynamic gadolinium-enhanced subtraction MR imaging — a simple technique for the early diagnosis of Legg–Calvé–Perthes disease: preliminary results. Pediatr Radiol 27:216–220CrossRefPubMed Sebag G, Ducou Le Pointe H, Klein I et al (1997) Dynamic gadolinium-enhanced subtraction MR imaging — a simple technique for the early diagnosis of Legg–Calvé–Perthes disease: preliminary results. Pediatr Radiol 27:216–220CrossRefPubMed
31.
Zurück zum Zitat Dillman JR, Hernandez RJ (2009) MRI of Legg–Calve–Perthes disease. AJR Am J Roentgenol 193:1394–1407CrossRefPubMed Dillman JR, Hernandez RJ (2009) MRI of Legg–Calve–Perthes disease. AJR Am J Roentgenol 193:1394–1407CrossRefPubMed
32.
Zurück zum Zitat Hundley WG, Bluemke DA, Finn JP et al (2010) ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance. A report of the American College of Cardiology foundation task force on expert consensus documents. Circulation 121:2462–2508CrossRefPubMed Hundley WG, Bluemke DA, Finn JP et al (2010) ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance. A report of the American College of Cardiology foundation task force on expert consensus documents. Circulation 121:2462–2508CrossRefPubMed
33.
Zurück zum Zitat Reiter T, Ritter O, Prince MR et al (2012) Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 14:31PubMedCentralCrossRefPubMed Reiter T, Ritter O, Prince MR et al (2012) Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 14:31PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Weller A, Barber JL, Olsen OE (2014) Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 29:1927–1937CrossRefPubMed Weller A, Barber JL, Olsen OE (2014) Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 29:1927–1937CrossRefPubMed
35.
Zurück zum Zitat Mendichovszky IA, Marks SD, Simcock CM et al (2008) Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol 38:489–496PubMedCentralCrossRefPubMed Mendichovszky IA, Marks SD, Simcock CM et al (2008) Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol 38:489–496PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat Nardone B, Saddleton E, Laumann AE et al (2014) Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr Radiol 44:173–180PubMedCentralCrossRefPubMed Nardone B, Saddleton E, Laumann AE et al (2014) Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr Radiol 44:173–180PubMedCentralCrossRefPubMed
37.
Zurück zum Zitat Elmholdt TR, Pedersen M, Jorgensen B et al (2011) Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case–control study from Denmark. Br J Dermatol 165:828–836CrossRefPubMed Elmholdt TR, Pedersen M, Jorgensen B et al (2011) Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case–control study from Denmark. Br J Dermatol 165:828–836CrossRefPubMed
38.
Zurück zum Zitat Elmholdt TR, Olesen ABB, Jorgensen B et al (2013) Nephrogenic systemic fibrosis in Denmark — a nationwide investigation. PLoSOne 8, e82037CrossRef Elmholdt TR, Olesen ABB, Jorgensen B et al (2013) Nephrogenic systemic fibrosis in Denmark — a nationwide investigation. PLoSOne 8, e82037CrossRef
Metadaten
Titel
Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies
verfasst von
Csilla Balassy
Donna Roberts
Stephen F. Miller
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Radiology / Ausgabe 12/2015
Print ISSN: 0301-0449
Elektronische ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-015-3394-9

Weitere Artikel der Ausgabe 12/2015

Pediatric Radiology 12/2015 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.